December 15th, 2015

Market Update (NASDAQ:BIIB): Biogen and Sobi Receive Positive Opinion from CHMP for ELOCTA™ (rFVIIIFc) for the Treatment of Hemophilia A

[Business Wire] – Biogen and Swedish Orphan Biovitrum AB received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use for the marketing authorization of ELOCTA™ . Read . . . → Read More: Market Update (NASDAQ:BIIB): Biogen and Sobi Receive Positive Opinion from CHMP for ELOCTA™ (rFVIIIFc) for the Treatment of Hemophilia A Similar Articles: Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Results from B-YOND Extension Study Reinforce Long-Term Clinical Profile of ALPROLIX for the Treatment of Hemophilia B Market Update: Biogen Idec Inc (NASDAQ:BIIB) – SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen, Inc. – BIIB Company Update: Biogen Idec Inc (NASDAQ:BIIB) – New Biogen Hemophilia Data At ISTH Congress to Highlight Extension Study Outcomes and Pediatric Use
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.